AllerPops
Liberate millions from allergies
Overview
Raised: $253,517
Rolling Commitments ($USD)
05/02/2021
507%
51%
$3,841
295
2016
Healthcare & Pharmaceuticals
Medtech
B2C
High
High
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$58,360 |
$20,549 |
COGS |
$8,327 |
$4,035 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-136,665 |
$-163,330 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$64,089 |
$4,916 |
Accounts Receivable |
$150 |
$0 |
Total Assets |
$204,095 |
$84,579 |
Short-Term Debt |
$17,342 |
$4,496 |
Long-Term Debt |
$199,131 |
$0 |
Total Liabilities |
$216,473 |
$4,496 |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Buy AllerPops's Deal Report
Warning: according to the close date for this deal, AllerPops may no longer be accepting investments.
Get KingsCrowd’s comprehensive report on AllerPops including:
- How our proprietary algorithm rates their current capital raise (1-5 stars)
- Detailed price, market, team, differentiators, performance, and risk ratings
- Whether AllerPops is undervalued or overvalued
- Scores on the founding team and key personnel's background and expertise
Buy the AllerPops deal report for only $10!